Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Immunol Methods ; 390(1-2): 9-17, 2013 Apr 30.
Article in English | MEDLINE | ID: mdl-21767540

ABSTRACT

Phagocytosis plays a pivotal and essential role in host immune defense, both as a focal constituent of the innate immune response and a bridging element linking innate and adaptive immunity. Phagocytosis has been demonstrated to be critical in development, tissue remodeling, wound healing and resolution of inflammation through clearance of foreign organisms, apoptotic cells and the production of anti-inflammatory mediators. During pre-clinical investigations, therapeutic drug candidates may alter host resistance to infectious agents by modulating the immune system. The assessment of phagocytic function can be a critical parameter of immunotoxicology for this adverse effect. Utilizing pH-sensitive pHrodo™ BioParticles®, a flow cytometric phagocytosis method was developed and validated in rodent and non-human primate (NHP) species under rigorous GLP compliant procedures. Using species-specific granulocyte markers as well as appropriate temperature and pharmacologic controls, we have developed an ex vivo assay to measure phagocytic function. The method has been optimized to utilize minimal sample volume of whole blood. The assay represents a rapid and reliable tool that can be implemented to evaluate the immunotoxic and immunomodulatory effects of therapeutic candidates.


Subject(s)
Flow Cytometry/methods , Granulocytes/immunology , Phagocytosis/immunology , Animals , Cytochalasin D/pharmacology , Dose-Response Relationship, Drug , Enzyme Inhibitors/pharmacology , Escherichia coli/immunology , Female , Granulocytes/metabolism , Macaca fascicularis , Macrolides/pharmacology , Male , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Nucleic Acid Synthesis Inhibitors/pharmacology , Phagocytosis/drug effects , Reproducibility of Results
2.
Protein Sci ; 15(5): 949-60, 2006 May.
Article in English | MEDLINE | ID: mdl-16597831

ABSTRACT

Improving the affinity of a high-affinity protein-protein interaction is a challenging problem that has practical applications in the development of therapeutic biomolecules. We used a combination of structure-based computational methods to optimize the binding affinity of an antibody fragment to the I-domain of the integrin VLA1. Despite the already high affinity of the antibody (Kd approximately 7 nM) and the moderate resolution (2.8 A) of the starting crystal structure, the affinity was increased by an order of magnitude primarily through a decrease in the dissociation rate. We determined the crystal structure of a high-affinity quadruple mutant complex at 2.2 A. The structure shows that the design makes the predicted contacts. Structural evidence and mutagenesis experiments that probe a hydrogen bond network illustrate the importance of satisfying hydrogen bonding requirements while seeking higher-affinity mutations. The large and diverse set of interface mutations allowed refinement of the mutant binding affinity prediction protocol and improvement of the single-mutant success rate. Our results indicate that structure-based computational design can be successfully applied to further improve the binding of high-affinity antibodies.


Subject(s)
Antibodies/therapeutic use , Antibody Affinity , Binding Sites, Antibody , Computer-Aided Design , Drug Design , Amino Acid Substitution , Antigen-Antibody Complex/chemistry , Crystallography, X-Ray , Immunoglobulins , Integrin alpha1beta1/immunology , Models, Molecular , Structure-Activity Relationship
3.
Anal Biochem ; 330(1): 98-113, 2004 Jul 01.
Article in English | MEDLINE | ID: mdl-15183767

ABSTRACT

To gauge the experimental variability associated with Biacore analysis, 36 different investigators analyzed a small molecule/enzyme interaction under similar conditions. Acetazolamide (222 g/mol) binding to carbonic anhydrase II (CAII; 30000 Da) was chosen as a model system. Both reagents were stable and their interaction posed a challenge to measure because of the low molecular weight of the analyte and the fast association rate constant. Each investigator created three different density surfaces of CAII and analyzed an identical dilution series of acetazolamide (ranging from 4.1 to 1000 nM). The greatest variability in the results was observed during the enzyme immobilization step since each investigator provided their own surface activating reagents. Variability in the quality of the acetazolamide binding responses was likely a product of how well the investigators' instruments had been maintained. To determine the reaction kinetics, the responses from the different density surfaces were fit globally to a 1:1 interaction model that included a term for mass transport. The averaged association and dissociation rate constants were 3.1+/-1.6 x 10(6)M(-1)s(-1) and 6.7+/-2.5 x 10(-2)s(-1), respectively, which corresponded to an average equilibrium dissociation constant (K(D) of 2.6+/-1.4 x 10(-8)M. The results provide a benchmark of variability in interpreting binding constants from the biosensor and highlight keys areas that should be considered when analyzing small molecule interactions.


Subject(s)
Acetazolamide/chemistry , Carbonic Anhydrase II/chemistry , Surface Plasmon Resonance , Acetazolamide/metabolism , Carbonic Anhydrase II/metabolism , Kinetics , Observer Variation , Protein Binding , Research Personnel , Surface Plasmon Resonance/instrumentation , Surface Plasmon Resonance/standards
4.
Biochemistry ; 41(8): 2543-51, 2002 Feb 26.
Article in English | MEDLINE | ID: mdl-11851401

ABSTRACT

Interleukin-2 is the primary T cell growth factor secreted by activated T cells. IL-2 is an alpha-helical cytokine that binds to a multisubunit receptor expressed on the surface of a variety of cell types. IL-2Ralpha, IL-2Rbeta, and IL-2Rgammac receptor subunits expressed on the surface of cells may aggregate to form distinct binding sites of differing affinities. IL-2Rgammac was the last receptor subunit to be identified. It has since been shown to be shared by at least five other cytokine receptors. In this study, we have probed the role of IL-2Rgammac in the assembly of IL-2R complexes and in ligand binding. We demonstrate that in the absence of ligand IL-2Rgammac does not possess detectable affinity for IL-2Ralpha, IL-2Rbeta, or the pseudo-high-affinity binding site composed of preformed IL-2Ralpha/beta. We also demonstrate that IL-2Rgammac possesses an IL-2-dependent affinity for IL-2Rbeta and IL-2Ralpha/beta. We performed a detailed biosensor analysis to examine the interaction of soluble IL-2Rgammac with IL-2-bound IL-2Rbeta and IL-2-bound IL-2Ralpha/beta. The kinetic and equilibrium constants for sIL-2Rgammac binding to these two different liganded complexes were similar, indicating that IL-2Ralpha does not play a role in recruitment of IL-2Rgammac. We also determined that the binding of IL-2 to the isolated IL-2Rgammac was very weak (approximate K(D) = 0.7 mM). The experimental methodologies and principles derived from these studies can be extended to at least five other cytokines that share IL-2Rgammac as a receptor subunit.


Subject(s)
Receptors, Interleukin-2/metabolism , Biosensing Techniques , Humans , Interleukin-2/metabolism , Kinetics , Ligands , Protein Binding , Radioligand Assay , Recombinant Proteins/metabolism , Tumor Cells, Cultured , Ultracentrifugation
SELECTION OF CITATIONS
SEARCH DETAIL
...